MeSH D008080 - liposarcoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Eisai | Eribulin | Halaven | 2023-07-20 | 2010-11-15 | ||
| Johnson & Johnson | Trabectedin | Yondelis | 2028-01-07 | 2015-10-23 | ||
| Pharma Mar | Trabectedin | Yondelis | 2007-09-17 |
Clinical Trials
Historical Success Rate
Phase 1
59%13/22
Phase 2
15%6/40
Phase 3
44%4/9
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use